Xiangjin Xu1, Lu Lin1, Pin Chen2, Yunjie Yu1, Shengping Chen1, Xiangqi Chen1, Zhulin Shao1. 1. 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, Fujian, China. 2. 900 Hospital of the Joint Logistics Team, Fuzong Clinical Medical College of Fujian Medical University, Fuzhou 350025, Fujian, China. Electronic address: chenpin@21cn.com.
Abstract
BACKGROUND: It has been reported that GLP-1 analogue can improve the skin lesions of psoriasis. However further research is needed to confirm that finding. OBJECTIVE: The study can provide further data regarding the efficacy and safety of GLP-1 analogue liraglutide in the treatment of psoriasis patients with type 2 diabetes. METHODS: We recruit 7 psoriasis patients with type 2 diabetes, and use hypodermic injection with liraglutide1.8 mg. In 12 weeks of treatment, we estimate the difference of before and after respectively, likeBMI, waist circumference, fasting blood glucose, fasting C-peptide, HbA1c, blood lipid levels, CRP, PASI, DLQI, skin tissue and pathological analysis of psoriasis. RESULTS: After 12 weeks of treatment, the mean value of PASI decreased from 15.7 ± 11.8 to 2.2 ± 3.0 (P = 0.03), while the DLQI decreased from 21.8 ± 6 to 4.1 ± 3.9 (P = 0.001). HbA1c was significantly improved after 12 weeks of treatment, decreased to 6.4 ± 0.8% (P = 0.04), the BMI decreased to 21 ± 3 kg m-2 (P < 0.01), and the waist circumference was also significantly improved to 83 ± 1 cm (P < 0.05). And 12 weeks after, the fasting C-peptide levels increased to 1.9 ± 0.5 ng/ml (P = 0.006), HOMA - IR fell to 1.6 ± 0.6 (P = 0.03). Histological analysis showed a reduction in epidermal thickness after treatment. The mean PASI decreased from 15.7 (1.5-31.3) to 2.0 (0.3-8.7) (P = 0.03), the DLQI decreased from 22 (8-27) to 4 (0-10) (P = 0.001). CONCLUSION: GLP-1 analogueliraglutide can improve the skin lesions of psoriasis patients with type 2 diabetes effectively, especially for extremely severe psoriasis patients. Its therapeutic effect may be related to anti-inflammatory, hypoglycemic and reducing weight.
BACKGROUND: It has been reported that GLP-1 analogue can improve the skin lesions of psoriasis. However further research is needed to confirm that finding. OBJECTIVE: The study can provide further data regarding the efficacy and safety of GLP-1 analogue liraglutide in the treatment of psoriasispatients with type 2 diabetes. METHODS: We recruit 7 psoriasispatients with type 2 diabetes, and use hypodermic injection with liraglutide1.8 mg. In 12 weeks of treatment, we estimate the difference of before and after respectively, likeBMI, waist circumference, fasting blood glucose, fasting C-peptide, HbA1c, blood lipid levels, CRP, PASI, DLQI, skin tissue and pathological analysis of psoriasis. RESULTS: After 12 weeks of treatment, the mean value of PASI decreased from 15.7 ± 11.8 to 2.2 ± 3.0 (P = 0.03), while the DLQI decreased from 21.8 ± 6 to 4.1 ± 3.9 (P = 0.001). HbA1c was significantly improved after 12 weeks of treatment, decreased to 6.4 ± 0.8% (P = 0.04), the BMI decreased to 21 ± 3 kg m-2 (P < 0.01), and the waist circumference was also significantly improved to 83 ± 1 cm (P < 0.05). And 12 weeks after, the fasting C-peptide levels increased to 1.9 ± 0.5 ng/ml (P = 0.006), HOMA - IR fell to 1.6 ± 0.6 (P = 0.03). Histological analysis showed a reduction in epidermal thickness after treatment. The mean PASI decreased from 15.7 (1.5-31.3) to 2.0 (0.3-8.7) (P = 0.03), the DLQI decreased from 22 (8-27) to 4 (0-10) (P = 0.001). CONCLUSION:GLP-1analogueliraglutide can improve the skin lesions of psoriasispatients with type 2 diabetes effectively, especially for extremely severe psoriasispatients. Its therapeutic effect may be related to anti-inflammatory, hypoglycemic and reducing weight.
Authors: Anna K O Rode; Terkild Brink Buus; Veronika Mraz; Fatima Abdul Hassan Al-Jaberi; Daniel Villalba Lopez; Shayne L Ford; Stephanie Hennen; Ina Primon Eliasen; Ib Vestergaard Klewe; Leila Gharehdaghi; Adrian Dragan; Mette M Rosenkilde; Anders Woetmann; Lone Skov; Niels Ødum; Charlotte M Bonefeld; Martin Kongsbak-Wismann; Carsten Geisler Journal: Cells Date: 2022-08-19 Impact factor: 7.666